A phase II, placebo-controlled study of vandetanib (ZD6474), which targets VEGFR, EGFR and RET signaling, showed activity in patients with inoperable HCC but failed to meet its primary aim of tumor stabilization [239]. This evidence concerns the gene KDR and hepatocellular carcinoma.